{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.2","upperLimit":"17.7","value":"10.9"},{"groupId":"OG001","lowerLimit":"2.3","upperLimit":"10.0","value":"5.1"},{"groupId":"OG002","lowerLimit":"0.3","upperLimit":"9.9","value":"2.6"}]}],"title":"CRi"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.8","upperLimit":"14.0","value":"7.8"},{"groupId":"OG001","lowerLimit":"0.7","upperLimit":"6.7","value":"2.6"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"5.9","value":"0.0"}]}],"title":"MLFS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"5.9","value":"1.6"},{"groupId":"OG001","lowerLimit":"3.2","upperLimit":"11.6","value":"6.4"},{"groupId":"OG002","lowerLimit":"0.3","upperLimit":"9.9","value":"2.6"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.2","upperLimit":"5.9","value":"1.6"},{"groupId":"OG001","lowerLimit":"0.1","upperLimit":"4.9","value":"1.3"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"5.9","value":"0.0"}]}],"title":"PRi"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.2","upperLimit":"17.7","value":"10.9"},{"groupId":"OG001","lowerLimit":"3.2","upperLimit":"11.6","value":"6.4"},{"groupId":"OG002","lowerLimit":"4.7","upperLimit":"19.9","value":"10.5"}]}],"title":"MR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"12.1","value":"6.3"},{"groupId":"OG001","lowerLimit":"11.3","upperLimit":"23.4","value":"16.7"},{"groupId":"OG002","lowerLimit":"12.7","upperLimit":"31.9","value":"21.1"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.9","upperLimit":"44.7","value":"35.9"},{"groupId":"OG001","lowerLimit":"7.1","upperLimit":"17.6","value":"11.5"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"5.9","value":"0.0"}]}],"title":"CRc"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.4","upperLimit":"46.2","value":"37.5"},{"groupId":"OG001","lowerLimit":"11.3","upperLimit":"23.4","value":"16.7"},{"groupId":"OG002","lowerLimit":"0.3","upperLimit":"9.9","value":"2.6"}]}],"title":"CRm"}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"78"},{"groupId":"OG002","value":"38"}],"units":"Participants"}],"description":"AML participants,disease specific efficacy measures included:CRi;Morphologic Leukemia Free State(MLFS)(bone marrow\\<5%myeloblasts with spicules and no blasts with auer rods,neutrophils\\<1000/mcL and platelets\\<100,000/mcL);partial remission(PR)(bone marrow myeloblasts decrease to 5-25\\&\\>=50%decrease from start, neutrophils\\>=1000/mcL, platelets\\>=100,000/mcL);PR with incomplete blood count recovery(PRi)(bone marrow myeloblasts decrease to 5-25\\&\\>=50%decrease from start,neutrophils\\<1000/mcL or platelets\\<100,000/mcL);minor response(MR)(bone marrow myeloblasts decrease to\\>=25% from start);stable disease(SD)(bone marrow myeloblasts stable+/-25% from screening value);cytogenetic complete response(CRc)(bone marrow\\<5%myeloblasts, neutrophils\\>1000/mcL, platelets\\>100,000/mcL and normal cytogenetics),molecular complete response(CRm)(bone marrow\\<5%myeloblasts, neutrophils\\>1000/mcL, platelets\\>100,000/mcL and molecular-negative).","dispersionType":"80% Confidence Interval","groups":[{"description":"Participants received 1-2 cycles of induction (glasdegib and daunorubicin/cytarabine), followed by 2-4 cycles of consolidation (glasdegib and high dose cytarabine) and a maximum of 6 cycles of maintenance (glasdegib alone). Daunorubicin was given on Days 1-3 QD at a dose of 60 mg/m\\^2/day by IV together with cytarabine on Days 1-7 at a dose of 100 mg/m\\^2/day by continuous IV infusion for each cycle of induction. Cytarabine was given on Days 1, 3, and 5 at a dose of 1 g/m\\^2 administered as a 3-hour IV infusion every 12 hours (2 g/m\\^2/day) for each cycle of consolidation. Glasdegib tablets 100 mg QD was started on induction Cycle 1/Day -3 and administered continuously QD thereafter for the duration of the study. A cycle was defined as 28 days.","id":"OG000","title":"Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin"},{"description":"Participants received oral doses of glasdegib tablets 100 mg QD in 28-day cycles on a continuous basis, starting on Day 1 of Cycle 1. LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28 day cycles.","id":"OG001","title":"Phase 2 Unfit: Glasdegib 100 mg + LDAC"},{"description":"Participants received LDAC subcutaneously at a dose of 20 mg BID on Days 1-10 of the 28 day cycles.","id":"OG002","title":"Phase 2 Unfit: LDAC Alone"}],"paramType":"NUMBER","populationDescription":"AML participants in the Full analysis set: all enrolled participants of Phase 2 Fit arm who received at least 1 dose of study medication, and all randomized participants of Phase 2 Unfit arm.","reportingStatus":"POSTED","timeFrame":"4 years","title":"Percentage of Participants With Disease-specific Efficacy for Acute Myeloid Leukemia (AML) at Phase 2 Fit and Unfit","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}